Zhang Yuhao, Chen Shao-Rui, Laumet Geoffroy, Chen Hong, Pan Hui-Lin
From the Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030.
From the Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030
J Biol Chem. 2016 Apr 15;291(16):8475-85. doi: 10.1074/jbc.M115.711812. Epub 2016 Feb 25.
The μ-opioid receptor (MOR, encoded by Oprm1) agonists are the mainstay analgesics for treating moderate to severe pain. Nerve injury causes down-regulation of MORs in the dorsal root ganglion (DRG) and diminishes the opioid effect on neuropathic pain. However, the epigenetic mechanisms underlying the diminished MOR expression caused by nerve injury are not clear. G9a (encoded by Ehmt2), a histone 3 at lysine 9 methyltransferase, is a key chromatin regulator responsible for gene silencing. In this study, we determined the role of G9a in diminished MOR expression and opioid analgesic effects in animal models of neuropathic pain. We found that nerve injury in rats induced a long-lasting reduction in the expression level of MORs in the DRG but not in the spinal cord. Nerve injury consistently increased the enrichment of the G9a product histone 3 at lysine 9 dimethylation in the promoter of Oprm1 in the DRG. G9a inhibition or siRNA knockdown fully reversed MOR expression in the injured DRG and potentiated the morphine effect on pain hypersensitivity induced by nerve injury. In mice lacking Ehmt2 in DRG neurons, nerve injury failed to reduce the expression level of MORs and the morphine effect. In addition, G9a inhibition or Ehmt2 knockout in DRG neurons normalized nerve injury-induced reduction in the inhibitory effect of the opioid on synaptic glutamate release from primary afferent nerves. Our findings indicate that G9a contributes critically to transcriptional repression of MORs in primary sensory neurons in neuropathic pain. G9a inhibitors may be used to enhance the opioid analgesic effect in the treatment of chronic neuropathic pain.
μ-阿片受体(由Oprm1编码的MOR)激动剂是治疗中度至重度疼痛的主要镇痛药。神经损伤会导致背根神经节(DRG)中MORs下调,并减弱阿片类药物对神经性疼痛的作用。然而,神经损伤导致MOR表达减少的表观遗传机制尚不清楚。G9a(由Ehmt2编码)是一种赖氨酸9组蛋白3甲基转移酶,是负责基因沉默的关键染色质调节因子。在本研究中,我们确定了G9a在神经性疼痛动物模型中MOR表达减少和阿片类镇痛作用中的作用。我们发现,大鼠的神经损伤导致DRG中MORs的表达水平长期降低,但脊髓中没有。神经损伤持续增加DRG中Oprm1启动子处G9a产物组蛋白3赖氨酸9二甲基化的富集。G9a抑制或siRNA敲低完全逆转了受损DRG中MOR的表达,并增强了吗啡对神经损伤诱导的疼痛超敏反应的作用。在DRG神经元中缺乏Ehmt2的小鼠中,神经损伤未能降低MORs的表达水平和吗啡的作用。此外,DRG神经元中的G9a抑制或Ehmt2基因敲除使神经损伤诱导的阿片类药物对初级传入神经突触谷氨酸释放抑制作用的降低恢复正常。我们的研究结果表明,G9a在神经性疼痛的初级感觉神经元中对MORs的转录抑制起关键作用。G9a抑制剂可用于增强阿片类镇痛作用,以治疗慢性神经性疼痛。